CompletedPHASE1, PHASE2NCT03226444
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
Studying Primary Sjögren disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TearSolutions, Inc.
- Principal Investigator
- Marc Odrich, MDTearSolutions, Inc.
- Intervention
- 0.005% Lacripep(drug)
- Enrollment
- 204 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- University of Alabama Eye Center, Birmingham, Alabama, United States
- Doctor My Eyes / Stephen Cohen, OD, PC, Scottsdale, Arizona, United States
- Schwartz Laser Eye Center, Scottsdale, Arizona, United States
- Milton M. Hom, OD FAAO FACAA (Sc), Azusa, California, United States
- University of California, Berkeley, School of Optometry, Berkeley, California, United States
- Orange County Ophthalmology, Garden Grove, California, United States
- Lugene Eye Institute, Glendale, California, United States
- Martel Eye Medical Group, Rancho Cordova, California, United States
- Wolstan & Goldberg Eye Associates, Torrance, California, United States
- University of Colorado Department of Ophthalmology, Aurora, Colorado, United States
- Corneal Consultants of Colorado, Littleton, Colorado, United States
- Bruce A. Segal, MD PA Private Practice, Delray Beach, Florida, United States
- Bowden Eye & Associates, Jacksonville, Florida, United States
- International Eye Associates, PA, Ormond Beach, Florida, United States
- Perez Eye Center, Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03226444 on ClinicalTrials.govOther trials for Primary Sjögren disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07118241A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASELubris Bio Pty Ltd
- RECRUITINGNANCT07324733Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET ImagingPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGNANCT06877546Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's SyndromeKoite Health Oy
- ENROLLING BY INVITATIONNCT06879444"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"Pamukkale University
- RECRUITINGPHASE3NCT06684847A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndromeargenx
- RECRUITINGPHASE2NCT06440525A Study of RSLV-132 in Females With Sjögren's DiseaseResolve Therapeutics
- ENROLLING BY INVITATIONPHASE2NCT06519617Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular DamageQingwen Tao
- RECRUITINGNCT06528197Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western MedicineChina-Japan Friendship Hospital